Bristol-Myers Squibb is a global biopharmaceutical company dedicated to discovering, developing, and delivering innovative medicines that help patients prevail over serious diseases
With a strong focus on oncology, immunology, cardiology, and fibrotic diseases, the company utilizes advanced science and research to create life-changing therapies. Bristol-Myers Squibb emphasizes collaboration and partnerships with healthcare professionals, researchers, and patients to enhance treatment outcomes and improve quality of life. The company is committed to addressing unmet medical needs through its comprehensive portfolio of prescription medications and is actively engaged in ongoing research to advance healthcare solutions.
I often discuss highly rated stocks that are part of highly rated sectors. Thus, this time is a departure from the norm. Let's dive into the data for the healthcare sector.
MyoKardia, a Bristol Myers unit, is terminating its agreement with Fulcrum Therapeutics, ending a cardiomyopathy research deal set to expire in June 2025.
Quarterly earnings results are a good time to check in on a company’s progress, especially compared to its peers in the same sector. Today we are looking at Bristol-Myers Squibb (NYSEBMY) and the best and worst performers in the branded pharmaceuticals industry.
Over the past six months, Bristol-Myers Squibb has been a great trade, beating the S&P 500 by 13.7%. Its stock price has climbed to $58.28, representing a healthy 18.8% increase. This run-up might have investors contemplating their next move.
Let's have a look at what is happening on the US markets one hour before the close of the markets on Monday. Below you can find the top S&P500 gainers and losers in today's session.
BRISTOL-MYERS SQUIBB CO has a stellar value proposition. NYSE:BMY not only scores well in profitability, solvency, and liquidity but also maintains a very reasonable price point.
Bristol Myers' Opdivo plus Yervoy gets FDA Priority Review for first-line MSI-H/dMMR metastatic colorectal cancer, with a decision expected by June 2025.
Exelixis reaffirmed its 2025 sales guidance of $2.15-$2.25 billion and reported sustained long-term efficacy for Cabometyx in advanced renal cell carcinoma.
Bristol Myers' Opdivo improved overall survival in resectable NSCLC, per final Phase 3 data. The study confirms its benefit when combined with chemotherapy.
Trump’s unpredictable tariff strategy is creating major market shifts. Discover how to read his next moves and uncover hidden investment opportunities before they take off.
Trump’s unpredictable tariff strategy is creating major market shifts. Discover how to read his next moves and uncover hidden investment opportunities before they take off.
Trump’s unpredictable tariff strategy is creating major market shifts. Discover how to read his next moves and uncover hidden investment opportunities before they take off.
